PROCTER & GAMBLE HEALTH LIMITED
Procter & Gamble Health Limited manufactures and markets pharmaceuticals and chemical products in India and internationally. The company offers over-the-counter products, vitamins, minerals, and supplements. It offers its products under the Polybion, Cosome, Evion, Neurobion, Nasivion, Livogen, and Seven Seas brands. The company was formerly known as Merck Limited and changed its name to Procter & Gamble Health Limited in May 2019. Procter & Gamble Health Limited was incorporated in 1967 and is headquartered in Mumbai, India. Procter & Gamble Health Limited is a subsidiary of Procter & Gamble Overseas India B.V.
Valuation
Profitability
Returns
Solvency
AI Summary
Indian StockStrengths1
- Valuation attractive β PE of 29.2x is 70% below Healthcare median of 98.6x
Concerns0
Rule-based from financial data. Not advice.
Monthly Returns
Year-to-Date ROI
Historical Volatility
Historical Performance
Revenue, profitability, and cash flow trends (βΉ Crores)
Revenue (10Y)
Operating Income (10Y)
Net Profit (10Y)
Operating Margin % (10Y)
Dividend Payout % (10Y)
Free Cash Flow (10Y)
Growth Summary
Latest fiscal year: Mar 2025
Historical Growth
Year-by-year revenue, profitability, and cash flow (βΉ Crores, last 10 years)
| Year | Revenue | Op. Income | Net Profit | CFO | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|---|
| Mar 2025 | β | β | β | β | β | β | β | β |
| Mar 2024 | βΉ1.15 K Cr | β | βΉ201.00 Cr | β | β | β | -6.4% | -12.2% |
| Mar 2023 | βΉ1.23 K Cr | β | βΉ229.00 Cr | β | β | β | 10.4% | 18.7% |
| Mar 2022 | βΉ1.11 K Cr | β | βΉ193.00 Cr | β | β | β | 10.4% | 9.0% |
| Mar 2021 | βΉ1.01 K Cr | β | βΉ177.00 Cr | β | β | β | -25.6% | -30.3% |
| Mar 2020 | β | β | β | β | β | β | β | β |
| Mar 2019 | βΉ927.00 Cr | β | βΉ159.00 Cr | β | β | β | 9.2% | -81.0% |
| Mar 2018 | βΉ849.00 Cr | β | βΉ839.00 Cr | β | β | β | 21.6% | 792.6% |
| Mar 2017 | βΉ698.00 Cr | β | βΉ94.00 Cr | β | β | β | -29.7% | 19.0% |
| Mar 2016 | βΉ993.00 Cr | β | βΉ79.00 Cr | β | β | β | 5.6% | 46.3% |
Financial Statements
Income statement, balance sheet, and cash flow (βΉ Crores, as reported)
Consolidated Figures in USD Millions.
| Unnamed: 0 | TTM |
|---|---|
| Revenue / Net Sales | 1,349 |
| Total Expenses | 947 |
| EBIT / Operating Profit | 402 |
| OPM % | 30 |
| Other Income | 16 |
| Finance Costs | 0 |
| Depreciation & Amortisation | 23 |
| Profit Before Tax | 395 |
| Tax % | - |
| Net Profit / PAT | 293 |
| EPS (βΉ) | 176.81 |
| Dividend Payout % | - |
Peer Comparison
Healthcare sector peers, ranked by market cap
| Company | Market Cap | Revenue | P/E | P/B | EV/EBITDA | Rev G 1Y |
|---|---|---|---|---|---|---|
| PROCTER & GAMBLE HEALTH LIMITEDthis co. | βΉ8.95 K Cr | βΉ934.00 Cr | 29.20 | 14.44 | 0.00 | -18.9% |
| Sun Pharmaceutical Industries Ltd. | βΉ4.15 L Cr | βΉ23.00 K Cr | 88.70 | 17.43 | 72.30 | 13.5% |
| Divi's Laboratories Ltd. | βΉ1.71 L Cr | βΉ9.20 K Cr | 67.90 | 11.13 | 67.21 | 20.0% |
| Torrent Pharmaceuticals Ltd. | βΉ1.33 L Cr | βΉ9.68 K Cr | 62.50 | 15.76 | 45.64 | 13.5% |
| Cipla Ltd. | βΉ1.17 L Cr | βΉ19.05 K Cr | 22.50 | 3.51 | 19.33 | 14.9% |
| Apollo Hospitals Enterprises Ltd. | βΉ1.05 L Cr | βΉ8.20 K Cr | 75.00 | 11.28 | 54.44 | 12.8% |
| Max Healthcare Institute Limited | βΉ1.00 L Cr | βΉ2.66 K Cr | 144.00 | 11.76 | 96.84 | 13.8% |
| Industry Average | β | βΉ3.29 K Cr | 98.63 | 8.11 | 65.50 | 20.2% |